Occlusal splint or botulinum toxin-a for jaw muscle pain treatment in probable sleep bruxism: A randomized controlled trial

被引:0
作者
Chisini, Luiz Alexandre [1 ]
Pires, Ana Luiza Cardoso [1 ]
Poletto-Neto, Victorio [1 ]
Damian, Melissa Feres [1 ]
Luz, Murilo Souza [2 ]
Loomans, Bas [3 ]
Pereira-Cenci, Tatiana [3 ]
机构
[1] Univ Fed Pelotas, Grad Program Dent, Pelotas, Brazil
[2] Atitus Educ, Dept Dent, Porto Alegre, Brazil
[3] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Dent, Nijmegen, Netherlands
关键词
Facial pain; Pain management; Chronic pain; Clinical Trial; TEMPOROMANDIBULAR-JOINT DISORDERS; MYOFASCIAL PAIN; ASSOCIATION; INJECTIONS; THERAPY; NETWORK;
D O I
10.1016/j.jdent.2024.105439
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: To conduct an equivalency randomized controlled trial comparing occlusal splint (OS) and botulinum toxin-A (BTX-A) on jaw muscle pain in probable sleep bruxism. Methods: Sixty patients (>= 18 years, probable sleep bruxism, and jaw muscle pain) were randomly allocated into groups. The primary outcome was the reduction of jaw muscle pain, assessed using the Graded Chronic Pain Scale (GCPS, v2.0). Secondary outcomes included: parameters of jaw opening and mandibular mobility; distribution of muscle pain; Jaw Functional Limitation Scale-20 (JFLS-20), Oral Behaviors Checklist (OBC); and Oral Health Impact Profile-14 (OHIP-14). Only the evaluator was blinded. Multilevel mixed-effects regression models were used. Results: Fifty-nine patients (30 received OS and 29 BTX-A) were analyzed at baseline, 3 and 6 months follow-up. One patient dropped out after receiving the intervention. No differences between the interventions were observed concerning the GCPS (p = 0.627), although a significant reduction was observed at 3 (OR=13.26, 95% CI[6.61-26.59]) and 6 months (OR=12.36, 95%CI[4.93-30.98]), regardless of the treatment. BTX-A showed a lower score reduction on JFLS-20 than OS (OR=0.29, 95%CI[0.11-0.82]). BTX-A presented inferior results for the parameters: opening without pain(p = 0.045), unassisted maximum opening(p = 0.024), assisted maximum opening(p = 0.041), and protrusion(p = 0.016). An improvement in OHIP-14 scores was observed at 3 (IRR=1.08, CI95%[1.02-1.14]) and 6 months (IRR=1.10, CI95%[1.04-1.16]), regardless of the intervention. BTX-A participants(n = 23;79,3%) reported mild discomfort during chewing. Conclusion: OS and BTX-A can effectively decrease the GCPS scores, improve OHRQoL, and enhance functional outcomes in sleep bruxist patients with jaw muscle pain. OS demonstrated slight advantages in specific parameters. Clinical Significance: Both occlusal splints and botulinum toxin-A effectively reduce jaw muscle pain in bruxist patients, improving quality of life and mandibular function. Clinically, occlusal splints may offer additional benefits in specific functional parameters. (NCT03456154)
引用
收藏
页数:10
相关论文
共 53 条
  • [1] Comparative analysis of different types of occlusal splints for the management of sleep bruxism: a systematic review
    Ainoosah, Sultan
    Farghal, Ahmed E.
    Alzemei, Marwa Saad
    Saini, Ravinder S.
    Gurumurthy, Vishwanath
    Quadri, Syed Altafuddin
    Okshah, Abdulmajeed
    Mosaddad, Seyed Ali
    Heboyan, Artak
    [J]. BMC ORAL HEALTH, 2024, 24 (01)
  • [2] Effectiveness of occlusal splint therapy in the management of temporomandibular disorders: network meta-analysis of randomized controlled trials
    Al-Moraissi, E. A.
    Farea, R.
    Qasem, K. A.
    Al-Wadeai, M. S.
    Al-Sabahi, M. E.
    Al-Iryani, G. M.
    [J]. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2020, 49 (08) : 1042 - 1056
  • [3] Al-Wayli Hessa, 2017, J Clin Exp Dent, V9, pe112, DOI 10.4317/jced.53084
  • [4] Possible mechanisms for the effects of botulinum toxin on pain
    Arezzo, JC
    [J]. CLINICAL JOURNAL OF PAIN, 2002, 18 (06) : S125 - S132
  • [5] The Evaluation of the Clinical Effects of Botulinum Toxin on Nocturnal Bruxism
    Asutay, Fatih
    Atalay, Yusuf
    Asutay, Hilal
    Acar, Ahmet Huseyin
    [J]. PAIN RESEARCH & MANAGEMENT, 2017, 2017
  • [6] Central origin of the antinociceptive action of botulinum toxin type A
    Bach-Rojecky, Lidija
    Lackovic, Zdravko
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2009, 94 (02) : 234 - 238
  • [7] Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews
    Canales, Giancarlo De la Torre
    Camara-Souza, Mariana Barbosa
    Ernberg, Malin
    Al-Moraissi, Essam Ahmed
    Grigoriadis, Anastasios
    Poluha, Rodrigo Lorenzi
    Christidis, Maria
    Jasim, Hajer
    Lovgren, Anna
    Christidis, Nikolaos
    [J]. DRUGS, 2024, 84 (07) : 779 - 809
  • [8] Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: what is the evidence regarding adverse effects?
    Canales, Giancarlo De la Torre
    Poluha, Rodrigo Lorenzi
    Lora, Victor Munoz
    Araujo Oliveira Ferreira, Dyna Mara
    Stuginski-Barbosa, Juliana
    Bonjardim, Leonardo Rigoldi
    Del Bel Cury, Altair Antoninha
    Rodrigues Conti, Paulo Cesar
    [J]. CLINICAL ORAL INVESTIGATIONS, 2019, 23 (09) : 3411 - 3421
  • [9] Therapies for sleep bruxism in dentistry: A critical evaluation of systematic reviews
    Ceron, Lissette
    Pacheco, Mishelle
    Delgado Gaete, Andres
    Bravo Torres, Wilson
    Astudillo Rubio, Daniela
    [J]. DENTAL AND MEDICAL PROBLEMS, 2023, 60 (02) : 335 - 344
  • [10] Effects of occlusal splint and exercise therapy, respectively, for the painful temporomandibular disorder in patients seeking for orthodontic treatment: a retrospective study
    Chen, Junjie
    Ning, Ruoyu
    Lu, Yanqin
    [J]. BMC ORAL HEALTH, 2022, 22 (01)